Bert Vogelstein
Affiliations: | Johns Hopkins University School of Medicine, Baltimore, MD, United States |
Area:
CancerWebsite:
http://www.hopkinsmedicine.org/pharmacology_molecular_sciences/faculty/bios/vogelstein.htmlGoogle:
"Bert Vogelstein"Bio:
Demonstrated that p53 was a tumor-suppressor gene.
Mean distance: 39813 | S | N | B | C | P |
Children
Sign in to add traineeCollaborators
Sign in to add collaboratorSandra B. Gabelli | collaborator | Johns Hopkins Medical School/HHMI |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Cook AL, Sur S, Dobbyn L, et al. (2023) Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape. Biorxiv : the Preprint Server For Biology |
Chan TA, Hermeking H, Lengauer C, et al. (2023) Author Correction: 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature |
Wright KM, DiNapoli SR, Miller MS, et al. (2023) Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen. Nature Communications. 14: 5063 |
Rincon-Torroella J, Molin MD, Mog B, et al. (2023) ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1. Biorxiv : the Preprint Server For Biology |
Lu S, Mattox AK, Aitana Azurmendi P, et al. (2023) The rapid and highly parallel identification of antibodies with defined biological activities by SLISY. Nature Communications. 14: 17 |
Cook AL, Wyhs N, Sur S, et al. (2022) An isogenic cell line panel for sequence-based screening of targeted anticancer drugs. Iscience. 25: 104437 |
Sengupta S, Board NL, Wu F, et al. (2022) TCR-mimic bispecific antibodies to target the HIV-1 reservoir. Proceedings of the National Academy of Sciences of the United States of America. 119: e2123406119 |
Pearlman AH, Hwang MS, Konig MF, et al. (2022) Author Correction: Targeting public neoantigens for cancer immunotherapy. Nature Cancer. 2: 865-867 |
Pearlman AH, Hwang MS, Konig MF, et al. (2021) Targeting public neoantigens for cancer immunotherapy. Nature Cancer. 2: 487-497 |
Caushi JX, Zhang J, Ji Z, et al. (2021) Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature |